Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biodesix, Inc. (BDSX) SEC filings page on Stock Titan brings together the company’s official disclosures as a Nasdaq-listed diagnostic solutions company. Through its reports to the U.S. Securities and Exchange Commission, Biodesix provides detail on its diagnostic testing and development services businesses, capital structure, and material corporate events.
Investors can use this page to access current and historical filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe revenue from Lung Diagnostics and Development Services, operating metrics, and risk factors relevant to a diagnostics and health care business. These core filings typically discuss Biodesix Diagnostic Tests marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, as well as the company’s work with biopharmaceutical and life sciences partners.
Biodesix also files Forms 8-K to report specific material events. Recent 8-K filings document actions such as a one-for-twenty reverse stock split of the company’s common stock, the related amendment to its certificate of incorporation, elimination of a preferred stock series, and confirmation that the company regained compliance with Nasdaq’s minimum bid price requirement. Other 8-Ks furnish press releases announcing quarterly financial and operating results.
On this page, users can review insider and capital structure-related filings when available, including information about changes to equity, preferred stock designations, and other securities. These documents help clarify how corporate actions affect common stockholders and outstanding awards or warrants.
Stock Titan enhances access to Biodesix filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify discussions of revenue composition, diagnostic and development services, stock listing matters, and significant corporate changes. Real-time updates from the EDGAR system ensure that new Biodesix 10-K, 10-Q, 8-K, and related filings appear promptly, while AI-generated overviews provide a starting point for deeper review of the full regulatory text.
Biodesix, Inc. reports strong 2025 growth as a lung‑focused diagnostics company. The business generated an estimated $88.5 million in total revenue, up 24% from 2024, driven mainly by its Biodesix Lung Diagnostic Testing segment.
Lung Diagnostic Testing produced $79.2 million of revenue from about 62,600 tests, increases of 22% and 15%, while Development Services contributed $9.3 million, up 41%. Gross margin improved to 81% from 78% as the company emphasized operational efficiencies and cost discipline, limiting operating expense growth (excluding direct costs and expenses) to 10% while revenue rose 24%.
Biodesix offers five blood‑based lung tests spanning nodule diagnosis, treatment guidance and monitoring, and estimates over 10 million annual testing opportunities in the U.S. representing a market of more than $27 billion. The company highlights expanding clinical data, growing reimbursement coverage, and multiple ongoing clinical studies, while operating CLIA‑certified, CAP‑accredited laboratories and maintaining an extensive intellectual property portfolio.
Biodesix reported strong fourth-quarter and full-year 2025 results, highlighted by rapid growth and improving profitability metrics. Q4 revenue reached
Net loss narrowed to
Biodesix Chief Development Officer Gary Anthony Pestano reported RSU vesting and a related tax sale. On February 20, 1,528 Restricted Stock Units were exercised into 1,528 shares of Biodesix common stock at $0.00 per share, as part of an annual vesting schedule starting February 20, 2025.
On February 23, 556 shares of common stock were sold at a weighted average price of $12.7756 per share by the issuer's broker to cover taxes due upon RSU vesting for certain employees, including Pestano. After these transactions, Pestano directly held 10,359 shares of common stock and 4,582 RSUs, which continue to vest in four equal annual installments.
Biodesix Inc.'s Chief Commercial Officer Kieran O'Kane reported insider transactions involving common stock and restricted stock units. On February 23, 2026, he sold 535 shares of common stock in an open-market transaction at a weighted average price of
Biodesix Inc (BDSX) CFO Robin Harper Cowie reported routine equity award activity and a small tax-related share sale. On February 20, 2026, 1,469 restricted stock units were exercised into 1,469 shares of common stock at a price of $0.00 per share, increasing directly held common stock to 16,766 shares.
On February 23, 2026, Cowie sold 535 shares of common stock in an open‑market transaction at a weighted average price of $12.7756 per share, leaving 16,231 common shares directly owned. Footnotes state these shares were sold automatically by the issuer’s broker to cover taxes upon RSU vesting, in multiple trades ranging from $12.58 to $13.16 per share.
Each RSU represents a right to receive one share of common stock, and the RSUs vest in four equal annual installments beginning February 20, 2025, generally subject to continued service. The holdings and award numbers reflect a one‑for‑twenty reverse stock split effective September 15, 2025.
Biodesix Inc Chief Accounting Officer Chris Vazquez reported equity transactions involving restricted stock units (RSUs) and common stock. On February 20, 2026, RSUs covering 563 shares were exercised for no cash cost, converting into the same number of common shares. Following this, on February 23, 2026, 211 common shares were sold in open-market transactions at a weighted average price of $12.7756 per share to cover taxes due upon RSU vesting, with individual sale prices ranging from $12.58 to $13.16. After these transactions, Vazquez directly held 1,586 common shares and 1,689 RSUs, with the RSUs scheduled to vest in four equal annual installments starting February 20, 2025.
Biodesix Inc. President & CEO Scott Hutton reported equity transactions involving company stock and restricted stock units. On
BDSX reports a Section 144 notice for the resale of 4,844 shares of common stock to settle vested RSUs under its S-8 plan. The filing also records prior open-market dispositions by Scott Hutton of 3,559 shares on
O'Kane Kieran reported multiple insider transaction types in a Form 4 filing for BDSX. The filing lists transactions totaling 3,784 shares at a weighted average price of $10.08 per share. Following the reported transactions, holdings were 9,469 shares.
Biodesix, Inc. Chief Accounting Officer Chris Vazquez reported equity award activity and a small share sale. On February 9, 2026, RSUs were converted into 263 shares of Common Stock, increasing direct holdings to 1,335 shares, and RSU positions were adjusted following a one-for-twenty reverse split.
On February 10, 2026, Vazquez executed an open‑market sale of 101 Common shares at a weighted average price of $10.0841, conducted automatically to cover taxes upon RSU vesting, leaving 1,234 Common shares held directly and 234 RSUs outstanding, which vest over time subject to continued service.